This article may need to be updated. Please update this article to reflect recent events or newly available information, and remove this template when finished.
|Systematic (IUPAC) name|
|Biological half-life||1.5-1.6 h|
129938-20-1 (HCl salt)
|ATC code||G04BX14 (WHO)|
|Molar mass||305.413 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
Dapoxetine (INN, brand name Priligy) is a short-acting selective serotonin reuptake inhibitor (SSRI) marketed for the treatment of premature ejaculation in men. Dapoxetine is the only drug with regulatory approval for such an indication. Currently, it is approved in several European countries, including Finland, Sweden, Portugal, Austria and Germany. Dapoxetine is also being considered for approval in other European countries and in the United States, where it is currently in Phase III of the U.S. Food and Drug Administration (FDA) approval process.
Several studies have suggested that dapoxetine has a benefit in the treatment of premature ejaculation. In a report published in the British Journal of Urology based on data from the phase III trial, authors conclude that dapoxetine is well-tolerated and improved measures associated with premature ejaculation, including reduction of personal distress, interpersonal difficulty and improvement in the satisfaction with the sexual intercourse.
Dapoxetine is the only approved medication to treat premature ejaculation.
Dapoxetine was created by Eli Lilly and Company and is credited to biochemist David T. Wong. Originally known as LY 210448, it was being developed by Lilly as an antidepressant. Eli Lilly sold the patent to Johnson & Johnson for $65 million and future royalties in December 2003. In 2004, dapoxetine was submitted to the FDA in the form of dapoxetine hydrochloride by the ALZA Corporation and its parent company, Johnson & Johnson, for the treatment of premature ejaculation with a New Drug Application (NDA). However, the FDA issued a "not approvable" letter for dapoxetine, requiring additional clinical study. Two further clinical trials were completed in 2006, and approval is under review by the FDA.
Dapoxetine has been submitted for approval in the European Union and is being reviewed. In 2009, dapoxetine received approval in Sweden, Finland, Austria, Portugal, Germany, Italy and Spain. Approvals for dapoxetine are also anticipated in other European countries as well. In addition, filings for approval have been submitted in Canada, Australia, Mexico, Turkey and six other countries.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
- "Premature Ejaculation Drug Promising"
- "The many mysteries of the female orgasm" - An editorial about advances in sexual pharmacology
- Sexual Health Portal - PE Disease Awareness Site for Patients, from J&J
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Johnson & Johnson Reports 2009 First-Quarter Results
- PPD Reports First Quarter 2009 Financial Results
- PRILIGY (Dapoxetin) erhält die Zulassung für die Behandlung der Ejaculatio praecox in Deutschland
- Janssen-Cilag EMEA announces receipt of first regulatory approvals for Priligy for PE in Finland and Sweden, February 11, 2009
- Safarinejad MR (2007). "Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study". Neuropsychopharmacology. 33 (6): 1259. doi:10.1038/sj.npp.1301500. PMID 17625501.
- News – Johnson & Johnson